Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 20, 2026.

Glucagon Receptor Signaling and Lipid Metabolism

Katrine D. Galsgaard, Jens Pedersen, Filip K. Knop and 2 more

Frontiers in Physiology · 2019

doi:10.3389/fphys.2019.00413

Abstract

Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic hyperglycemia. Antagonists of the glucagon receptor have been considered as glucose-lowering therapy in type 2 diabetes patients, but their clinical applicability has been questioned because of reports of therapy-induced increments in liver fat content and increased plasma concentrations of low-density lipoprotein. Conversely, in animal models, increased glucagon receptor signaling has been linked to improved lipid metabolism. Glucagon acts primarily on the liver and by regulating hepatic lipid metabolism glucagon may reduce hepatic lipid accumulation and decrease hepatic lipid secretion. Regarding whole-body lipid metabolism, it is controversial to what extent glucagon influences lipolysis in adipose tissue, particularly in humans. Glucagon receptor agonists combined with glucagon-like peptide 1 receptor agonists (dual agonists) improve dyslipidemia and reduce hepatic steatosis. Collectively, emerging data support an essential role of glucagon for lipid metabolism.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Glucagon is processed from its precursor, proglucagon, by prohormone convertase 2 and secreted from pancreatic alpha cells. The role of glucagon in glucose metabolism has been intensively studied, and comprehensive reviews are found elsewhere. In addition to regulating glucose metabolism, glucagon also seems important for minute-to-minute regulation of amino acid metabolism as part of the recently described liver-alpha cell axis, in which amino acids stimulate glucagon secretion and glucagon in turn stimulates hepatic amino acid uptake and metabolism (ureagenesis) and, thus, circulating amino acid concentrations as well as increased hepatic NADH/NAD+ ratio. The actions of glucagon are mediated via the glucagon receptor, a seven transmembrane receptor coupled to Gαs- and Gq-proteins, which regulate adenylate cyclase (AC) and phospholipase C activities when activated. The glucagon receptor is primarily expressed in the liver, but it is also expressed in varying amounts in the central nervous system, kidneys, gastro-intestinal tract, heart (controversial), and pancreas.

Glucagon receptor expression has been reported in rat adipocytes, where a lipolytic effect of glucagon may be of physiological relevance. As type 2 diabetic hyperglucagonaemia contributes to the hyperglycemic state of patients with type 2 diabetes (T2D), inhibition of glucagon receptor signaling has been investigated as glucose-lowering therapy in T2D patients. Interestingly, potential adverse effects of this therapeutic approach include increased low-density lipoprotein (LDL) plasma concentrations and increased hepatic fat accumulation. Furthermore, hepatocyte studies have shown that glucagon stimulates beta-oxidation, inhibits lipogenesis and decrease triglyceride (TG) and very-low-density lipoprotein (VLDL) secretion emphasizing a potentially important role of glucagon in lipid metabolism.

Glucagon Might Stimulate Lipolysis in Adipose Tissue in Rodents but Not in Humans

Lipolysis in adipocytes depends on activation of AC and thereby increased protein kinase A (PKA) activity. PKA phosphorylates (hence activates) perilipins and hormone-sensitive lipase (HSL), and two additional lipases, resulting in hydrolysis of TGs and release of glycerol and free fatty acids (FFAs), e.g., palmitate (;;;;; Figure 1). Circulating levels of FFAs and glycerol therefore reflect the rate of lipolysis. For glucagon to directly influence adipocyte function, its cognate receptor must be expressed. Glucagon receptor mRNA has been detected in rat adipocytes, but to determine the physiological relevance of glucagon receptor mRNA expression, it is necessary to investigate whether the mRNA is actually translated into a functional receptor. Specific antibodies directed against the glucagon receptor are necessary in addressing this question, but development of specific antibodies against glucagon receptors has been challenging and the antibodies available are unspecific and therefore not suitable for receptor localization. As an example, one study reported localization of the glucagon receptor in rat adipocytes using a monoclonal antibody whereas another using autoradiography, glucagon receptors were not found to be expressed, and no studies have demonstrated presence of glucagon receptors on human adipocytes. Clearly, future studies should investigate glucagon receptor expression using antibody and antibody-independent methods.

Glucagon has been reported to activate HSL and lipolysis in rat adipocytes within minutes at concentrations as low as 6 × 10−10 M and 10−11 M. Glucagon has also been shown to stimulate lipolysis in birds, rabbits, and human adipocytes in vitro at concentrations near 10−8 M. At physiological plasma concentrations (1–40 pM), a lipolytic effect of glucagon in human adipocytes has been difficult to demonstrate. One of the first human studies reporting a lipolytic effect of glucagon, demonstrated that an injection of 7.5 μg glucagon into the branchial artery resulted in a rapid increase in FFA plasma concentrations in the corresponding vein but this was not replicated in a similar study with mean increases of glucagon plasma concentrations by 237 pM in overnight fasted subjects. An increase in FFA plasma concentrations has been demonstrated upon glucagon infusion (mean glucagon increment 209 ± 15 pM) and intravenous injection of glucagon [reaching plasma concentrations of >1,000 pM]. Since supra-physiological glucagon concentrations were applied, these studies may lack specificity because of interaction of glucagon with other related G protein-coupled receptors (e.g., the glucagon-like peptide 1 (GLP-1) receptor). Pharmacological concentrations of glucagon also stimulate secretion of catecholamines and growth hormone, both of which have powerful lipolytic effects, possibly as part of a generalized sympathetic nervous system discharge. Glucagon was not found to have any lipolytic effects in clinical studies using glucagon concentrations ranging from 19 to 64 pM. In some clinical studies investigating the lipolytic effect of supra-physiological glucagon concentrations, the lipolytic effect of glucagon could be abolished by insulin, and in rat adipocytes insulin is a potent inhibitor of lipolysis. A lipolytic effect of glucagon, if any, on human adipocytes may therefore only be physiologically relevant when insulin secretion is low. Supporting this, a 2-h infusion of 1 ng/kg × min glucagon (presumably resulting in physiologically relevant elevations) and somatostatin in insulin-deficient diabetic subjects caused a two to three-fold increase in FFA and glycerol plasma concentrations, compared to infusion of somatostatin alone. However, when insulin, somatostatin, and glucagon were infused together, glucagon had no lipolytic effect. Furthermore, infusion with saline only gave the same increase in FFA as compared to glucagon infusion. In another study glucagon was infused at 1.2 ng/kg × min (high but also relevant) together with somatostatin for 2 h, but there was no lipolytic effect of glucagon at insulin concentrations of 38 pM. In contrast, a 2-h glucagon infusion at 1.3 ng/kg × min, during a mean insulin plasma concentration of 65 pM, increased the rate of appearance of labeled FFA and glycerol by 40 and 36%, respectively. As glucagon receptors are expressed on beta cells and may stimulate insulin secretion through both GLP-1 and glucagon receptors it may be speculated that intraislet regulation of insulin through glucagon may contribute to its effect on lipid metabolism.

It is important to note that FFA and glycerol in plasma are not only determined by release from adipocytes, but also by rate of uptake and re-esterification in other tissues. A lack of effect of glucagon on the free plasma pool of FFA and glycerol, does therefore not rule out that glucagon has a direct effect on lipid metabolism in adipocytes and hepatocytes (Figure 1).

Glucagon Stimulates Hepatic Beta-Oxidation and Inhibits Lipogenesis

In hepatocytes, glucagon action increases the transcription factor cAMP responsive element binding (CREB) protein, which induces the transcription of carnitine acyl transferase 1 (CPT-1). CPT-1 enables catabolism of long-chain fatty acids by converting fatty acids to acyl-carnitines, which are transported into the mitochondria and subjected to beta-oxidation. During beta-oxidation the fatty acids are degraded into acetate, which ultimately enters the citric acid cycle. Furthermore, through PKA-dependent phosphorylation, glucagon receptor signaling inactivates acetyl-CoA carboxylase, the enzyme catalyzing the formation of malonyl-CoA. Malonyl-CoA is the first intermediate in fatty acid synthesis and inhibits CPT-1 (i.e., inhibits beta-oxidation). By inhibiting the formation of malonyl-CoA, glucagon diverts FFAs to beta-oxidation rather than re-esterification into TGs (Figure 2). Periportal and perivenous hepatocytes receive different concentrations of substrates and oxygen and as a consequence periportal hepatocytes primarily mediate oxidative processes, including beta-oxidation, whereas perivenous hepatocytes preferentially mediate glucose uptake and lipogenesis.

In hepatocytes, glucagon may bring about an energy-depleted state (increasing the AMP/ATP ratio) sufficient to activate AMP-activated kinase, which phosphorylates acetyl-CoA carboxylase and p38 mitogen-activated protein kinase, leading to transcriptional activation of peroxisome proliferator-activated receptor-α (PPARα). PPARα stimulates the transcription of genes involved in beta-oxidation including CPT-1, CPT-2, and acetyl-CoA oxidase, and the transcription of fibroblast growth factor 21, which is produced in the liver in response to glucagon. Glucagon also stimulates forkhead transcription factor A2 activity (FoxA2), which induces transcription of genes involved in beta-oxidation, such as CPT-1, very-, and medium- long-chain acyl-CoA dehydrogenase. Subsequent to activating its receptors on hepatocytes, insulin suppresses most of these pathways, and the metabolic state in the hepatocytes may therefore be determined by the insulin-glucagon ratio, rather than by the hormone concentrations per se. Insulin inhibits lipolysis in adipocytes and by reducing the amount of substrate (FFA and glycerol) reaching the liver may reduce hepatic gluconeogenesis.

To investigate the physiological effects of glucagon in lipid metabolism, several studies have relied on glucagon receptor knockout (Gcgr−/−) mice or animals treated with GRA. In the livers of Gcgr−/− mice there is an increase in glycolysis and a decrease in gluconeogenesis and citric acid cycle activity, which results in decreased acetyl-CoA oxidation and acetyl-CoA accumulation. The accumulation of acetyl-CoA in the cytosol of hepatocytes results in increased lipogenesis. Supporting this, genes involved in lipogenesis, e.g., ATP citrate lyase and fatty acid synthase, were found to be upregulated in livers of Gcgr−/− mice at both the mRNA and protein level, while CPT-1 and -2 levels, and other enzymes necessary for beta-oxidation, were downregulated. Hepatic beta-oxidation is essential for the production of both glucose and ketones since it provides the substrates acetyl-CoA and acetate and mitochondrial energy supply (ATP/NADH) needed for gluconeogenesis. The hepatic gene expression profile changes markedly in response to fasting, and major differences have been reported in expression levels of genes involved in lipid metabolism between the fed and fasted state. Following a prolonged fast (16 h), wild-type mice had an increased hepatic expression of genes involved in beta-oxidation, such as CPT-1, CPT-2, and acyl-CoA dehydrogenase, but this was not observed in Gcgr−/− mice, which displayed an impaired beta-oxidation in both the fasted and fed state and Gcgr−/− mice failed to change the hepatic energy state in response to fasting. Furthermore, Gcgr−/− mice showed increased hepatic TG secretion and increased plasma concentrations of TG and FFA after a 16 h fasting period, but not after 5 h of fasting. Others also found similar TG and FFA plasma concentrations in Gcgr−/− and wild-type mice after a short-term fast; they did, however, find increased plasma concentrations of LDL in Gcgr−/− mice. Glucagon thus seems to regulate hepatic metabolism in response to fasting by stimulating glucose-producing processes, including beta-oxidation. When challenged with a high fat diet (HFD) for 8 weeks, Gcgr−/− mice did not increase the amount of inguinal and epididymal fat, whereas the amount of both doubled in wild-type mice. In line with this, others showed a decrease in white adipose tissue mass and an increase in lean body mass in Gcgr−/− compared to wild-type mice, without changes in bodyweight, food consumption, or energy expenditure and one group found that Gcgr−/− mice had lower amounts of white adipose tissue when fed both a HFD and a low fat diet compared to wild-type mice, and thus seemed to be resistant to diet-induced obesity. This could reflect an inability of Gcgr−/− mice to mobilize the hepatic lipid storage; instead adipocyte lipolysis (by catecholamines) maintain the energy supply to other metabolically active tissues.

Implications of Glucagon Receptor Signaling in the Development of Steatosis

Administration of GRAs has been associated with increased hepatic fat content (assessed as hepatic fat fraction measured by magnetic resonance imaging) and increased plasma concentrations of LDL. Furthermore, subjects with endogenous glucagon deficiency (pancreatectomized subjects) and rats and diabetic (db/db) mice treated with glucagon antisense oligonucleotide have increased hepatic fat. These data suggest that inhibition of glucagon receptor signaling results in hepatic lipid accumulation. In addition, Gcgr−/− mice may be prone to steatosis when challenged with a high fat diet (HFD) for 8 weeks. However, a study involving a similar HFD diet for 12 weeks and mice with the same sex, gene modification, and background (C57BL/6J), showed that Gcgr−/− mice were protected from steatosis. Of notice, C57BL/6J mice do not consistently develop steatosis upon HFD feeding, and this might have influenced the results. In rats, impaired glucagon action also associates with development of hepatic steatosis. Interestingly, HFD feeding has been reported to decrease glucagon receptor expression at the plasma membrane of rat hepatocytes. These data suggest that hepatic lipid accumulation may cause impaired glucagon receptor signaling, and that this (as demonstrated using GRAs) may contribute to and accelerate hepatic lipid accumulation.

Acute administration of 30 μg/kg glucagon decreased FFA and TG plasma concentrations and reduced hepatic TG content and secretion in mice. Chronic hyperglucagonemia (injection of 10 μg glucagon every 8 h for 21 days) had hypolipidemic effects in rats, evident by a 70 and 38% decrease in plasma concentrations of TGs and phospholipids, respectively. Consistent with this, glucagon inhibited synthesis and secretion of TGs in cultured hepatocytes, in perfused rat livers, and decreased the synthesis of hepatic VLDL in rats. In humans, hyperglucagonemia (56 ± 20 pM), during a pancreatic clamp, reduced hepatic lipoprotein particle turnover, and glucagon administration increased hepatic beta-oxidation in humans. In diet-induced obese (DIO) mice, a once-weekly treatment with 70 nmol/kg glucagon/GLP-1 receptor co-agonist resulted in loss of fat mass, which in the same study was also found, although less pronounced in GLP-1 receptor knockout mice, and improved hepatic lipid metabolism and steatosis within 4 weeks. Another glucagon/GLP-1 co-agonist (1.9 μmol/kg daily for 14 days) decreased acetyl-CoA and malonyl-CoA concentrations and increased CPT-1 mRNA in the livers of DIO mice, whereas a selective GLP-1 receptor agonist had no effect. Both of these dual agonists reduced hepatic steatosis, increased HSL activity in adipocytes, and improved dyslipidemia in DIO mice. Supporting these data, other glucagon/GLP-1 receptor co-agonists have been reported to lower plasma concentrations of TG and cholesterol, decrease hepatic fat content, and reduce adipose mass in rodent models of T2D and obesity. Importantly, acute administration of 25 nmol/kg glucagon/GLP-1 co-agonist decreased plasma concentration of TGs, cholesterol, and LDL in DIO mice within 1 h, whereas liraglutide (a pure GLP-1 receptor agonist) administration had no effect. In addition, hepatic synthesis of VLDL and palmitate, and fatty acid esterification decreased, while beta-oxidation and LDL receptors expression increased upon co-agonist, but not liraglutide, administration. The inhibitory effect on hepatic lipogenesis and stimulatory effect on beta-oxidation therefore seems to be mediated by glucagon receptor signaling. Several clinical studies are currently investigating the potential treatment of obesity and T2D using glucagon/GLP-1 co-agonists.

Regulation of Glucagon Secretion by Lipids

FFAs are under certain circumstances insulin secretagogs but their ability to stimulate glucagon secretion remains debated. Some clinical studies found a suppression of glucagon secretion at increased FFA concentrations whereas isolated alpha cells were shown to secrete glucagon in response to FFA stimulation. In isolated rat pancreatic islets, palmitate stimulated glucagon secretion. Others found palmitate to stimulate glucagon secretion in a glucose-dependent manner using isolated pancreatic islets; increasing at glucose concentrations of 2.8, 5.6, and 10 mM but not at 16.7 mM. Medium and long-chain fatty acids (>C5) have been reported to stimulate glucagon secretion by activation of FFA receptor G protein-coupled receptor 40 (GPR40) and GPR119, both present in the pancreatic islets. FFAs may also function as metabolic substrate and stimulate alpha cell secretion through beta-oxidation. FFAs decrease secretion of somatostatin, and may lower the tonic inhibition of somatostatin on alpha cells. A clinical study investigating the effects of ingestion of lipids on hormone secretion, found no change in glucagon secretion after intravenous or oral administration of a lipid emulsion (3 ml/kg), neither did glucagon plasma concentrations change upon a 300 min lipid infusion raising FFA plasma concentrations from 0.4 to 0.8 mM. No difference in glucagon secretion was observed between subjects consuming a HFD or a low-fat diet for 2 weeks. In contrast to this, ingestion of long–chain fatty acids (olive oil and C8 fatty acids) lead to increased plasma concentrations of glucagon 40 min after, whereas no increase was observed after ingestion of short-chain fatty acids (C4), however, glucose-dependent insulinotropic polypeptide (GIP) concentrations also increased upon ingestion of long-chain fatty acids and this may have caused an increase in glucagon secretion. Another study observed that a meal rich in mono-unsaturated fatty acids resulted in a larger glucagon response when compared to a control meal. Others also observed an increase in glucagon concentrations upon fat-enriched meals. The glucagon response observed upon a 90 min intraduodenal infusion of linoleic, oleic, and palmitic acids were significant lower than observed upon protein infusion. Studies of ability of FFAs to stimulate glucagon secretion are complex, since FFAs are found in many forms and their stimulatory effect may vary [as is the case for incretin secretion]. Furthermore, the increased glucagon concentrations reported in some studies may result from other proglucagon products (e.g., glicentin or oxyntomodulin), since measurements of plasma glucagon concentrations have been marred with problems regarding sensitivity and specificity, and further studies investigating the regulation of glucagon secretion by FFAs are needed.

Conclusion

Glucagon may, aside from its physiological actions on glucose and amino acid metabolism, also be important for lipid metabolism via effects on hepatic beta-oxidation and lipogenesis, and potentially increased lipolysis in adipocytes. A direct role of glucagon on adipocytes may be of importance in rodents, as glucagon stimulates lipolysis, whereas in humans an adipocyte-dependent lipolysis of glucagon is more complex. In both rodents and humans, glucagon is a powerful regulator of hepatic lipid metabolism as highlighted in studies using GRAs. The clinical use of GRAs is further challenged by glucagon’s role in amino acid metabolism, and blocking the glucagon receptor results in hyperaminoacidemia and eventually alpha cell hyperplasia. Treatment of diabetes using the current GRAs may therefore not be feasible, however, one may speculate that targeted antagonism of glucagon signaling may circumvent these unwarranted side-effects. Currently glucagon receptor agonists, combined with GLP-1 and GIP receptor agonists, are investigated as possible therapeutic agents. In preclinical studies, these agents improve steatosis and dyslipidemia, possibly as a consequence of regulation of hepatic lipid metabolism by glucagon agonism.

Taken together, glucagon seems to play an important physiological role in the acute regulation of lipid metabolism but clearly further studies particularly in humans are warranted.

Author Contributions

All authors wrote and approved the final edition of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 147

  1. 1.
    Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets · 2016
    No notice
  2. 2.

    Ahren B. (2015 ). Glucagon-early breakthroughs and recent discoveries. Peptides 67 74–81.

    Not in our library10.1016/j.peptides.2015.03.011

  3. 3.

    Anthonsen M. W. Ronnstrand L. Wernstedt C. Degerman E. Holm C. (1998 ). Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J. Biol. Chem. 273 215–221.

    Not in our library10.1074/jbc.273.1.215

  4. 4.

    Aromataris E. C. Roberts M. L. Barritt G. J. Rychkov G. Y. (2006 ). Glucagon activates Ca2+ and Cl- channels in rat hepatocytes. J. Physiol. 573(Pt 3), 611–625.

    Not in our library10.1113/jphysiol.2006.109819

  5. 5.

    Baron A. D. Schaeffer L. Shragg P. Kolterman O. G. (1987 ). Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36 274–283.

    Not in our library10.2337/diab.36.3.274

  6. 6.

    Berglund E. D. Lee-Young R. S. Lustig D. G. Lynes S. E. Donahue E. P. Camacho R. C. (2009 ). Hepatic energy state is regulated by glucagon receptor signaling in mice. J. Clin. Invest. 119 2412–2422.

    Not in our library10.1172/jci38650

  7. 7.

    Bobe G. Ametaj B. N. Young J. W. Beitz D. C. (2003 ). Effects of exogenous glucagon on lipids in lipoproteins and liver of lactating dairy cows. J. Dairy Sci. 86 2895–2903.

    Not in our library10.3168/jds.s0022-0302(03)73886-7

  8. 8.

    Boden G. Carnell L. H. (2003 ). Nutritional effects of fat on carbohydrate metabolism. Best Pract. Res. Clin. Endocrinol. Metab. 17 399–410.

    Not in our library10.1016/s1521-690x(03)00032-0

  9. 9.

    Bollheimer L. C. Landauer H. C. Troll S. Schweimer J. Wrede C. E. Scholmerich J. (2004 ). Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 53 1443–1448.

    Not in our library10.1016/j.metabol.2004.06.011

  10. 10.

    Briant L. J. B. Dodd M. S. Chibalina M. V. Rorsman N. J. G. Johnson P. R. V. Carmeliet P. (2018 ). CPT1a-dependent long-chain fatty acid oxidation contributes to maintaining glucagon secretion from pancreatic islets. Cell Rep. 23 3300–3311.

    Not in our library10.1016/j.celrep.2018.05.035

  11. 11.

    Briscoe C. P. Tadayyon M. Andrews J. L. Benson W. G. Chambers J. K. Eilert M. M. (2003 ). The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278 11303–11311.

    Not in our library10.1074/jbc.m211495200

  12. 12.

    Capozzi M. E. DiMarchi R. D. Tschop M. H. Finan B. Campbell J. E. (2018 ). Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr. Rev. 39 719–738.

    Not in our library10.1210/er.2018-00117

  13. 13.

    Carlson M. G. Snead W. L. Campbell P. J. (1993 ). Regulation of free fatty acid metabolism by glucagon. J. Clin. Endocrinol. Metab. 77 11–15.

    Not in our library10.1210/jcem.77.1.8100827

  14. 14.

    Carranza M. C. Simon M. A. Torres A. Romero B. Calle C. (1993 ). Identification of glucagon receptors in human adipocytes from a liposarcoma. J. Endocrinol. Invest. 16 439–442.

    Not in our library10.1007/bf03348878

  15. 15.

    Charbonneau A. Couturier K. Gauthier M. S. Lavoie J. M. (2005a ). Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int. J. Sports Med. 26 432–441.

    Not in our library10.1055/s-2004-821225

  16. 16.

    Charbonneau A. Melancon A. Lavoie C. Lavoie J. M. (2005b ). Alterations in hepatic glucagon receptor density and in Gsalpha and Gialpha2 protein content with diet-induced hepatic steatosis: effects of acute exercise. Am. J. Physiol. Endocrinol. Metab. 289 E8–E14.

    Not in our library10.1152/ajpendo.00570.2004

  17. 17.

    Charbonneau A. Unson C. G. Lavoie J. M. (2007 ). High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. J. Physiol. 579(Pt 1), 255–267.

    Not in our library10.1113/jphysiol.2006.121954

  18. 18.

    Charlton M. Krishnan A. Viker K. Sanderson S. Cazanave S. McConico A. (2011 ). Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am. J. Physiol. Gastrointest. Liver Physiol. 301 G825–G834.

    Not in our library10.1152/ajpgi.00145.2011

  19. 19.

    Clemmensen C. Chabenne J. Finan B. Sullivan L. Fischer K. Kuchler D. (2014 ). GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63 1422–1427.

    Not in our library10.2337/db13-1609

  20. 20.

    Collins S. C. Salehi A. Eliasson L. Olofsson C. S. Rorsman P. (2008 ). Long-term exposure of mouse pancreatic islets to oleate or palmitate results in reduced glucose-induced somatostatin and oversecretion of glucagon. Diabetologia 51 1689–1693.

    Not in our library10.1007/s00125-008-1082-0

  21. 21.

    Conarello S. L. Jiang G. Mu J. Li Z. Woods J. Zycband E. (2007 ). Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50 142–150.

    Not in our library10.1007/s00125-006-0481-3

  22. 22.

    Cyphert H. A. Alonge K. M. Ippagunta S. M. Hillgartner F. B. (2014 ). Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS One 9:e94996.

    Not in our library10.1371/journal.pone.0094996

  23. 23.

    Day J. W. Ottaway N. Patterson J. T. Gelfanov V. Smiley D. Gidda J. (2009 ). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5 749–757.

    Not in our library10.1038/nchembio.209

  24. 24.

    Dean E. D. Li M. Prasad N. Wisniewski S. N. Von Deylen A. Spaeth J. (2017 ). Interrupted glucagon signaling reveals hepatic alpha-cell axis and role for l-glutamine in alpha-cell proliferation. Cell Metab. 25 1362–1373.e5.

    Not in our library10.1016/j.cmet.2017.05.011

  25. 25.

    DiMarco J. P. Hoppel C. (1975 ). Hepatic mitochondrial function in ketogenic states. Diabetes, starvation, and after growth hormone administration. J. Clin. Invest. 55 1237–1244.

    Not in our library10.1172/jci108042

  26. 26.

    Dresler C. M. Fortner J. G. McDermott K. Bajorunas D. R. (1991 ). Metabolic consequences of (regional) total pancreatectomy. Ann. Surg. 214 131–140.

    Not in our library10.1097/00000658-199108000-00007

  27. 27.

    Dumonteil E. Magnan C. Ritz-Laser B. Ktorza A. Meda P. Philippe J. (2000 ). Glucose regulates proinsulin and prosomatostatin but not proglucagon messenger ribonucleic acid levels in rat pancreatic islets. Endocrinology 141 174–180.

    Not in our library10.1210/endo.141.1.7230

  28. 28.

    Eaton R. P. (1973 ). Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J. Lipid Res. 14 312–318.

    Not in our library

  29. 29.

    Edwards J. C. Taylor K. W. (1970 ). Fatty acids and the release of glucagon from isolated guinea-pig islets of Langerhans incubated in vitro. Biochim. Biophys. Acta 215 310–315.

    Not in our library10.1016/0304-4165(70)90029-2

  30. 30.

    Egan J. J. Greenberg A. S. Chang M. K. Wek S. A. Moos M. C. Jr. Londos C. (1992 ). Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. Proc. Natl. Acad. Sci. U.S.A. 89 8537–8541.

    Not in our library10.1073/pnas.89.18.8537

  31. 31.

    Evers A. Haack T. Lorenz M. Bossart M. Elvert R. Henkel B. (2017 ). Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. J. Med. Chem. 60 4293–4303.

    Not in our library10.1021/acs.jmedchem.7b00174

  32. 32.

    Faerch K. Vistisen D. Pacini G. Torekov S. S. Johansen N. B. Witte D. R. (2016 ). Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes 65 3473–3481.

    Not in our library10.2337/db16-0240

  33. 33.

    Feltrin K. L. Little T. J. Meyer J. H. Horowitz M. Smout A. J. Wishart J. (2004 ). Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287 R524–R533.

    Not in our library10.1152/ajpregu.00039.2004

  34. 34.

    Galsgaard K. D. Winther-Sørensen M. Ørskov C. Kissow H. Poulsen S. S. Vilstrup H. (2017 ). Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver - alpha-cell axis. Am. J. Physiol. Endocrinol. Metab. 314 E93–E103.

    Not in our library10.1152/ajpendo.00198.2017

  35. 35.

    Garton A. J. Campbell D. G. Cohen P. Yeaman S. J. (1988 ). Primary structure of the site on bovine hormone-sensitive lipase phosphorylated by cyclic AMP-dependent protein kinase. FEBS Lett. 229 68–72.

    Not in our library10.1016/0014-5793(88)80799-3

  36. 36.

    Gelling R. W. Du X. Q. Dichmann D. S. Romer J. Huang H. Cui L. (2003 ). Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100 1438–1443.

    Not in our library10.1073/pnas.0237106100

  37. 37.

    Gerich J. E. Langlois M. Schneider V. Karam J. H. Noacco C. (1974 ). Effects of alternations of plasma free fatty acid levels on pancreatic glucagon secretion in man. J. Clin. Invest. 53 1284–1289.

    Not in our library10.1172/jci107675

  38. 38.

    Gerich J. E. Lorenzi M. Bier D. M. Tsalikian E. Schneider V. Karam J. H. (1976 ). Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J. Clin. Invest. 57 875–884.

    Not in our library10.1172/jci108364

  39. 39.

    Goldfine I. D. Cerasi E. Luft R. (1972 ). Glucagon stimulation of insulin release in man: inhibition during hypoglycemia. J. Clin. Endocrinol. Metab. 35 312–315.

    Not in our library10.1210/jcem-35-2-312

  40. 40.

    Granneman J. G. Moore H. P. Krishnamoorthy R. Rathod M. (2009 ). Perilipin controls lipolysis by regulating the interactions of AB-hydrolase containing 5 (Abhd5) and adipose triglyceride lipase (Atgl). J. Biol. Chem. 284 34538–34544.

    Not in our library10.1074/jbc.m109.068478

  41. 41.

    Gravholt C. H. Moller N. Jensen M. D. Christiansen J. S. Schmitz O. (2001 ). Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J. Clin. Endocrinol. Metab. 86 2085–2089.

    Not in our library10.1210/jc.86.5.2085

  42. 42.

    Greenberg A. S. Egan J. J. Wek S. A. Garty N. B. Blanchette-Mackie E. J. Londos C. (1991 ). Perilipin, a major hormonally regulated adipocyte-specific phosphoprotein associated with the periphery of lipid storage droplets. J. Biol. Chem. 266 11341–11346.

    Not in our library

  43. 43.

    Gremlich S. Bonny C. Waeber G. Thorens B. (1997 ). Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J. Biol. Chem. 272 30261–30269.

    Not in our library10.1074/jbc.272.48.30261

  44. 44.

    Gromada J. Franklin I. Wollheim C. B. (2007 ). Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28 84–116.

    Not in our library10.1210/er.2006-0007

  45. 45.

    Gromada J. Hoy M. Buschard K. Salehi A. Rorsman P. (2001 ). Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules. J. Physiol. 535(Pt 2), 519–532.

    Not in our library10.1111/j.1469-7793.2001.00519.x

  46. 46.

    Gross R. Mialhe P. (1986 ). Free fatty acids and pancreatic function in the duck. Acta Endocrinol. 112 100–104.

    Not in our library10.1530/acta.0.1120100

  47. 47.

    Gu W. Lloyd D. J. Chinookswong N. Komorowski R. Sivits G. Jr. Graham M. (2011 ). Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice. J. Pharmacol. Exp. Ther. 338 70–81.

    Not in our library10.1124/jpet.111.179986

  48. 48.

    Guettet C. Mathe D. Riottot M. Lutton C. (1988 ). Effects of chronic glucagon administration on cholesterol and bile acid metabolism. Biochim. Biophys. Acta 963 215–223.

    Not in our library10.1016/0005-2760(88)90283-4

  49. 49.

    Guzman C. B. Zhang X. M. Liu R. Regev A. Shankar S. Garhyan P. (2017 ). Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes. Metab. 19 1521–1528.

    Not in our library10.1111/dom.12958

  50. 50.

    Guzman M. Castro J. (1989 ). Zonation of fatty acid metabolism in rat liver. Biochem. J. 264 107–113.

    Not in our library10.1042/bj2640107

  51. 51.

    Hansen H. S. Rosenkilde M. M. Holst J. J. Schwartz T. W. (2012 ). GPR119 as a fat sensor. Trends Pharmacol. Sci. 33 374–381.

    Not in our library10.1016/j.tips.2012.03.014

  52. 52.

    Hansen L. H. Abrahamsen N. Nishimura E. (1995 ). Glucagon receptor mRNA distribution in rat tissues. Peptides 16 1163–1166.

    Not in our library10.1016/0196-9781(95)00078-x

  53. 53.

    Heckemeyer C. M. Barker J. Duckworth W. C. Solomon S. S. (1983 ). Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell. Endocrinology 113 270–276.

    Not in our library10.1210/endo-113-1-270

  54. 54.

    Heimberg M. Weinstein I. Kohout M. (1969 ). The effects of glucagon, dibutyryl cyclic adenosine 3’,5’-monophosphate, and concentration of free fatty acid on hepatic lipid metabolism. J. Biol. Chem. 244 5131–5139.

    Not in our library

  55. 55.

    Henderson S. J. Konkar A. Hornigold D. C. Trevaskis J. L. Jackson R. Fritsch Fredin M. (2016 ). Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 18 1176–1190.

    Not in our library10.1111/dom.12735

  56. 56.

    Hjorth S. A. Adelhorst K. Pedersen B. B. Kirk O. Schwartz T. W. (1994 ). Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J. Biol. Chem. 269 30121–30124.

    Not in our library

  57. 57.

    Holst J. J. Holland W. Gromada J. Lee Y. Unger R. H. Yan H. (2017a ). Insulin and glucagon: partners for life. Endocrinology 158 696–701.

    Not in our library10.1210/en.2016-1748

  58. 58.

    Holst J. J. Wewer Albrechtsen N. J. Pedersen J. Knop F. K. (2017b ). Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis. Diabetes 66 235–240.

    Not in our library10.2337/db16-0994

  59. 59.

    Honnor R. C. Dhillon G. S. Londos C. (1985 ). cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators. J. Biol. Chem. 260 15130–15138.

    Not in our library

  60. 60.

    Iwanij V. Vincent A. C. (1990 ). Characterization of the glucagon receptor and its functional domains using monoclonal antibodies. J. Biol. Chem. 265 21302–21308.

    Not in our library

  61. 61.

    Jelinek L. J. Lok S. Rosenberg G. B. Smith R. A. Grant F. J. Biggs S. (1993 ). Expression cloning and signaling properties of the rat glucagon receptor. Science 259 1614–1616.

    Not in our library10.1126/science.8384375

  62. 62.

    Jensen M. D. Heiling V. J. Miles J. M. (1991 ). Effects of glucagon on free fatty acid metabolism in humans. J. Clin. Endocrinol. Metab. 72 308–315.

    Not in our library10.1210/jcem-72-2-308

  63. 63.

    Jiang G. Zhang B. B. (2003 ). Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284 E671–E678.

    Not in our library10.1152/ajpendo.00492.2002

  64. 64.

    Jungermann K. (1988 ). Metabolic zonation of liver parenchyma. Semin. Liver Dis. 8 329–341.

    Not in our library10.1055/s-2008-1040554

  65. 65.

    Kazda C. M. Ding Y. Kelly R. P. Garhyan P. Shi C. Lim C. N. (2016 ). Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies. Diabetes Care 39 1241–1249.

    Not in our library10.2337/dc15-1643

  66. 66.

    Kazierad D. J. Bergman A. Tan B. Erion D. M. Somayaji V. Lee D. S. (2016 ). Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 18 795–802.

    Not in our library10.1111/dom.12672

  67. 67.

    Kazierad D. J. Chidsey K. Somayaji V. R. Bergman A. J. Calle R. A. (2018 ). Efficacy and safety of the glucagon receptor antagonist PF-06291874: a 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy. Diabetes Obes. Metab. 20 2608–2616.

    Not in our library10.1111/dom.13440

  68. 68.

    Kim J. Okamoto H. Huang Z. Anguiano G. Chen S. Liu Q. (2017 ). Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic alpha-cell hyperplasia in mice. Cell Metab. 25 1348–1361.e8.

    Not in our library10.1016/j.cmet.2017.05.006

  69. 69.

    Kim J. Y. Hickner R. C. Cortright R. L. Dohm G. L. Houmard J. A. (2000 ). Lipid oxidation is reduced in obese human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 279 E1039–E1044.

    Not in our library10.1152/ajpendo.2000.279.5.e1039

  70. 70.

    Kristinsson H. Sargsyan E. Manell H. Smith D. M. Gopel S. O. Bergsten P. (2017 ). Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion. Sci. Rep. 7:4657.

    Not in our library10.1038/s41598-017-04730-5

  71. 71.

    Lass A. Zimmermann R. Haemmerle G. Riederer M. Schoiswohl G. Schweiger M. (2006 ). Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman syndrome. Cell Metab. 3 309–319.

    Not in our library10.1016/j.cmet.2006.03.005

  72. 72.

    Lefebvre P. Luyckx A. Bacq Z. M. (1973 ). Effects of denervation on the metabolism and the response to glucagon of white adipose tissue of rats. Horm. Metab. Res. 5 245–250.

    Not in our library10.1055/s-0028-1093959

  73. 73.

    Lefebvre P. J. Luyckx A. S. (1969 ). Effect of insulin on glucagon enhanced lipolysis in vitro. Diabetologia 5 195–197.

    Not in our library10.1007/bf01213680

  74. 74.

    Li N. X. Brown S. Kowalski T. Wu M. Yang L. Dai G. (2018 ). GPR119 agonism increases glucagon secretion during insulin-induced hypoglycemia. Diabetes 67 1401–1413.

    Not in our library10.2337/db18-0031

  75. 75.

    Liang Y. Osborne M. C. Monia B. P. Bhanot S. Gaarde W. A. Reed C. (2004 ). Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53 410–417.

    Not in our library10.2337/diabetes.53.2.410

  76. 76.

    Liljenquist J. E. Bomboy J. D. Lewis S. B. Sinclair-Smith B. C. Felts P. W. Lacy W. W. (1974 ). Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J. Clin. Invest. 53 190–197.

    Not in our library10.1172/jci107537

  77. 77.

    Lindgren O. Carr R. D. Deacon C. F. Holst J. J. Pacini G. Mari A. (2011 ). Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J. Clin. Endocrinol. Metab. 96 2519–2524.

    Not in our library10.1210/jc.2011-0266

  78. 78.

    Livingston J. N. Cuatrecasas P. Lockwood D. H. (1974 ). Studies of glucagon resistance in large rat adipocytes: 125I-labeled glucagon binding and lipolytic capacity. J. Lipid Res. 15 26–32.

    Not in our library

  79. 79.

    Longuet C. Sinclair E. M. Maida A. Baggio L. L. Maziarz M. Charron M. J. (2008 ). The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 8 359–371.

    Not in our library10.1016/j.cmet.2008.09.008

  80. 80.

    Luyckx A. S. Lefebvre P. J. (1970 ). Arguments for a regulation of pancreatic glucagon secretion by circulating plasma free fatty acids. Proc. Soc. Exp. Biol. Med. 133 524–528.

    Not in our library10.3181/00379727-133-34511

  81. 81.

    Madison L. L. Seyffert W. A. Jr. Unger R. H. Barker B. (1968 ). Effect on plasma free fatty acids on plasma glucagon and serum insulin concentrations. Metabolism 17 301–304.

    Not in our library10.1016/0026-0495(68)90097-8

  82. 82.

    Mandoe M. J. Hansen K. B. Hartmann B. Rehfeld J. F. Holst J. J. Hansen H. S. (2015 ). The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans. Am. J. Clin. Nutr. 102 548–555.

    Not in our library10.3945/ajcn.115.106799

  83. 83.

    Manganiello V. Vaughan M. (1972 ). Selective loss of adipose cell responsiveness to glucagon with growth in the rat. J. Lipid Res. 13 12–16.

    Not in our library

  84. 84.

    Mitchell M. L. Byrne M. J. Silver J. (1969 ). Growth-hormone release by glucagon. Lancet 1 289–290.

    Not in our library10.1016/s0140-6736(69)91041-1

  85. 85.

    More V. R. Lao J. McLaren D. G. Cumiskey A. M. Murphy B. A. Chen Y. (2017 ). Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice. PLoS One 12:e0186586.

    Not in our library10.1371/journal.pone.0186586

  86. 86.

    Mosinger B. Kuhn E. Kujalová V. (1965 ). Action of adipokinetic hormones on human adipose tissue in vitro. J. Lab. Clin. Med. 66 380–389.

    Not in our library

  87. 87.

    Müller T. D. Finan B. Clemmensen C. DiMarchi R. D. Tschöp M. H. (2017 ). The new biology and pharmacology of glucagon. Physiol. Rev. 97 721–766.

    Not in our library10.1152/physrev.00025.2016

  88. 88.

    Niederwanger A. Ciardi C. Tatarczyk T. Khan M. I. Hermann M. Mittermair C. (2014 ). Postprandial lipemia induces pancreatic alpha cell dysfunction characteristic of type 2 diabetes: studies in healthy subjects, mouse pancreatic islets, and cultured pancreatic alpha cells. Am. J. Clin. Nutr. 100 1222–1231.

    Not in our library10.3945/ajcn.114.092023

  89. 89.

    Olofsson C. S. Salehi A. Gopel S. O. Holm C. Rorsman P. (2004 ). Palmitate stimulation of glucagon secretion in mouse pancreatic alpha-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium. Diabetes 53 2836–2843.

    Not in our library10.2337/diabetes.53.11.2836

  90. 90.

    Parrilla R. Goodman M. N. Toews C. J. (1974 ). Effect of glucagon: insulin ratios on hepatic metabolism. Diabetes 23 725–731.

    Not in our library10.2337/diab.23.9.725

  91. 91.

    Paschoalini M. A. Migliorini R. H. (1990 ). Participation of the CNS in the control of FFA mobilization during fasting in rabbits. Physiol. Behav. 47 461–465.

    Not in our library10.1016/0031-9384(90)90109-h

  92. 92.

    Patsouris D. Reddy J. K. Muller M. Kersten S. (2006 ). Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147 1508–1516.

    Not in our library10.1210/en.2005-1132

  93. 93.

    Pegorier J. P. Garcia-Garcia M. V. Prip-Buus C. Duee P. H. Kohl C. Girard J. (1989 ). Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment. Biochem. J. 264 93–100.

    Not in our library10.1042/bj2640093

  94. 94.

    Peng I. C. Chen Z. Sun W. Li Y. S. Marin T. L. Hsu P. H. (2012 ). Glucagon regulates ACC activity in adipocytes through the CAMKKbeta/AMPK pathway. Am. J. Physiol. Endocrinol. Metab. 302 E1560–E1568.

    Not in our library10.1152/ajpendo.00504.2011

  95. 95.

    Penhos J. C. Wu C. H. Daunas J. Reitman M. Levine R. (1966 ). Effect of glucagon on the metabolism of lipids and on urea formation by the perfused rat liver. Diabetes 15 740–748.

    Not in our library10.2337/diab.15.10.740

  96. 96.

    Perea A. Clemente F. Martinell J. Villanueva-Penacarrillo M. L. Valverde I. (1995 ). Physiological effect of glucagon in human isolated adipocytes. Horm. Metab. Res. 27 372–375.

    Not in our library10.1055/s-2007-979981

  97. 97.

    Perry R. J. Camporez J. G. Kursawe R. Titchenell P. M. Zhang D. Perry C. J. (2015 ). Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160 745–758.

    Not in our library10.1016/j.cell.2015.01.012

  98. 98.

    Pettus J. Reeds D. Cavaiola T. S. Boeder S. Levin M. Tobin G. (2018 ). Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 20 1302–1305.

    Not in our library10.1111/dom.13202

  99. 99.

    Pocai A. Carrington P. E. Adams J. R. Wright M. Eiermann G. Zhu L. (2009 ). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58 2258–2266.

    Not in our library10.2337/db09-0278

  100. 100.

    Pozefsky T. Tancredi R. G. Moxley R. T. Dupre J. Tobin J. D. (1976 ). Metabolism of forearm tissues in man. Studies with glucagon. Diabetes 25 128–135.

    Not in our library10.2337/diab.25.2.128

  101. 101.

    Pozza G. Pappalettera A. Melogli O. Viberti G. Ghidoni A. (1971 ). Lipolytic effect of intra-arterial injection of glucagon in man. Horm. Metab. Res. 3 291–292.

    Not in our library10.1055/s-0028-1096783

  102. 102.

    Prigge W. F. Grande F. (1971 ). Effects of glucagon, epinephrine and insulin on in vitro lipolysis of adipose tissue from mammals and birds. Comp. Biochem. Physiol. B 39 69–82.

    Not in our library10.1016/0305-0491(71)90254-9

  103. 103.

    Prip-Buus C. Pegorier J. P. Duee P. H. Kohl C. Girard J. (1990 ). Evidence that the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA is an important site of regulation of hepatic fatty acid oxidation in the fetal and newborn rabbit. Perinatal development and effects of pancreatic hormones in cultured rabbit hepatocytes. Biochem. J. 269 409–415.

    Not in our library10.1042/bj2690409

  104. 104.

    Raben A. Holst J. J. Madsen J. Astrup A. (2001 ). Diurnal metabolic profiles after 14 d of an ad libitum high-starch, high-sucrose, or high-fat diet in normal-weight never-obese and postobese women. Am. J. Clin. Nutr. 73 177–189.

    Not in our library10.1093/ajcn/73.2.177

  105. 105.

    Radulescu A. Gannon M. C. Nuttall F. Q. (2010 ). The effect on glucagon, glucagon-like peptide-1, total and acyl-ghrelin of dietary fats ingested with and without potato. J. Clin. Endocrinol. Metab. 95 3385–3391.

    Not in our library10.1210/jc.2009-2559

  106. 106.

    Ramnanan C. J. Edgerton D. S. Kraft G. Cherrington A. D. (2011 ). Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes. Metab. 13(Suppl. 1), 118–125.

    Not in our library10.1111/j.1463-1326.2011.01454.x

  107. 107.

    Richter W. O. Robl H. Schwandt P. (1989 ). Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro. Peptides 10 333–335.

    Not in our library10.1016/0196-9781(89)90039-9

  108. 108.

    Rodbell M. Jones A. B. (1966 ). Metabolism of isolated fat cells. 3. The similar inhibitory action of phospholipase C (Clostridium perfringens alpha toxin) and of insulin on lipolysis stimulated by lipolytic hormones and theophylline. J. Biol. Chem. 241 140–142.

    Not in our library

  109. 109.

    Rouille Y. Westermark G. Martin S. K. Steiner D. F. (1994 ). Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc. Natl. Acad. Sci. U.S.A. 91 3242–3246.

    Not in our library10.1073/pnas.91.8.3242

  110. 110.

    Ryan A. T. Luscombe-Marsh N. D. Saies A. A. Little T. J. Standfield S. Horowitz M. (2013 ). Effects of intraduodenal lipid and protein on gut motility and hormone release, glycemia, appetite, and energy intake in lean men. Am. J. Clin. Nutr. 98 300–311.

    Not in our library10.3945/ajcn.113.061333

  111. 111.

    Sadry S. A. Drucker D. J. (2013 ). Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9 425–433.

    Not in our library10.1038/nrendo.2013.47

  112. 112.

    Samols E. Marri G. Marks V. (1965 ). Promotion of insulin secretion by glucogen. Lancet 2 415–416.

    Not in our library10.1016/s0140-6736(65)90761-0

  113. 113.
    GLP-1/glucagon receptor co-agonism for treatment of obesity · 2017
    No notice
  114. 114.

    Schade D. S. Eaton R. P. (1975 ). Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects. Diabetes 24 502–509.

    Not in our library10.2337/diabetes.24.5.502

  115. 115.

    Schneider S. H. Fineberg S. E. Blackburn G. L. (1981 ). The acute metabolic effects of glucagon and its interactions with insulin in forearm tissue. Diabetologia 20 616–621.

    Not in our library10.1007/bf00257430

  116. 116.

    Schweiger M. Eichmann T. O. Taschler U. Zimmermann R. Zechner R. Lass A. (2014 ). Measurement of lipolysis. Methods Enzymol. 538 171–193.

    Not in our library10.1016/b978-0-12-800280-3.00010-4

  117. 117.

    Shen W. J. Patel S. Miyoshi H. Greenberg A. S. Kraemer F. B. (2009 ). Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. J. Lipid Res. 50 2306–2313.

    Not in our library10.1194/jlr.m900176-jlr200

  118. 118.

    Slavin B. G. Ong J. M. Kern P. A. (1994 ). Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J. Lipid Res. 35 1535–1541.

    Not in our library

  119. 119.

    Sloop K. W. Cao J. X. Siesky A. M. Zhang H. Y. Bodenmiller D. M. Cox A. L. (2004 ). Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J. Clin. Invest. 113 1571–1581.

    Not in our library10.1172/jci20911

  120. 120.

    Sloth B. Due A. Larsen T. M. Holst J. J. Heding A. Astrup A. (2009 ). The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. Br. J. Nutr. 101 1846–1858.

    Not in our library10.1017/s0007114508137710

  121. 121.

    Solloway M. J. Madjidi A. Gu C. Eastham-Anderson J. Clarke H. J. Kljavin N. (2015 ). Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of alpha-cell mass. Cell Rep. 12 495–510.

    Not in our library10.1016/j.celrep.2015.06.034

  122. 122.

    Staehr P. Hother-Nielsen O. Landau B. R. Chandramouli V. Holst J. J. Beck-Nielsen H. (2003 ). Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes 52 260–267.

    Not in our library10.2337/diabetes.52.2.260

  123. 123.

    Stallknecht B. Simonsen L. Bulow J. Vinten J. Galbo H. (1995 ). Effect of training on epinephrine-stimulated lipolysis determined by microdialysis in human adipose tissue. Am. J. Physiol. 269(6 Pt 1), E1059–E1066.

    Not in our library10.1152/ajpendo.1995.269.6.e1059

  124. 124.

    Stephens F. B. Constantin-Teodosiu D. Greenhaff P. L. (2007 ). New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J. Physiol. 581(Pt 2), 431–444.

    Not in our library10.1113/jphysiol.2006.125799

  125. 125.

    Stralfors P. Bjorgell P. Belfrage P. (1984 ). Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. Proc. Natl. Acad. Sci. U.S.A. 81 3317–3321.

    Not in our library10.1073/pnas.81.11.3317

  126. 126.

    Svendsen B. Larsen O. Gabe M. B. N. Christiansen C. B. Rosenkilde M. M. Drucker D. J. (2018 ). Insulin secretion depends on intra-islet glucagon signaling. Cell Rep 25 1127–1134.e2.

    Not in our library10.1016/j.celrep.2018.10.018

  127. 127.

    Svoboda M. Tastenoy M. Vertongen P. Robberecht P. (1994 ). Relative quantitative analysis of glucagon receptor mRNA in rat tissues. Mol. Cell. Endocrinol. 105 131–137.

    Not in our library10.1016/0303-7207(94)90162-7

  128. 128.

    Thomsen C. Rasmussen O. Lousen T. Holst J. J. Fenselau S. Schrezenmeir J. (1999 ). Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am. J. Clin. Nutr. 69 1135–1143.

    Not in our library10.1093/ajcn/69.6.1135

  129. 129.

    Unger R. H. Orci L. (1975 ). The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1 14–16.

    Not in our library10.1016/s0140-6736(75)92375-2

  130. 130.

    Vajda E. G. Logan D. Lasseter K. Armas D. Plotkin D. J. Pipkin J. D. (2017 ). Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes. Metab. 19 24–32.

    Not in our library10.1111/dom.12752

  131. 131.

    van der Woning B. De Boeck G. Blanchetot C. Bobkov V. Klarenbeek A. Saunders M. (2016 ). DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops. MAbs 8 1126–1135.

    Not in our library10.1080/19420862.2016.1189050

  132. 132.

    Vaughan M. Berger J. E. Steinberg D. (1964 ). Hormone-sensitive lipase and monoglyceride lipase activities in adipose tissue. J. Biol. Chem. 239 401–409.

    Not in our library

  133. 133.

    Vaughan M. Steinberg D. (1963 ). Effect of hormones on lipolysis and esterification of free fatty acids during incubation of adipose tissue in vitro. J. Lipid Res. 4 193–199.

    Not in our library

  134. 134.

    Vizek K. Razova M. Melichar V. (1979 ). Lipolytic effect of TSH, glucagon and hydrocortisone on the adipose tissue of newborns and adults in vitro. Physiol. Bohemoslov. 28 325–331.

    Not in our library

  135. 135.

    von Meyenn F. Porstmann T. Gasser E. Selevsek N. Schmidt A. Aebersold R. (2013 ). Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. Cell Metab. 17 436–447.

    Not in our library10.1016/j.cmet.2013.01.014

  136. 136.

    Wakelam M. J. Murphy G. J. Hruby V. J. Houslay M. D. (1986 ). Activation of two signal-transduction systems in hepatocytes by glucagon. Nature 323 68–71.

    Not in our library10.1038/323068a0

  137. 137.

    Wang H. Hu L. Dalen K. Dorward H. Marcinkiewicz A. Russell D. (2009 ). Activation of hormone-sensitive lipase requires two steps, protein phosphorylation and binding to the PAT-1 domain of lipid droplet coat proteins. J. Biol. Chem. 284 32116–32125.

    Not in our library10.1074/jbc.m109.006726

  138. 138.

    Wang L. Zhao Y. Gui B. Fu R. Ma F. Yu J. (2011 ). Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet {alpha}-cells. J. Endocrinol. 210 173–179.

    Not in our library10.1530/joe-11-0132

  139. 139.

    Watanabe M. Hayasaki H. Tamayama T. Shimada M. (1998 ). Histologic distribution of insulin and glucagon receptors. Braz. J. Med. Biol. Res. 31 243–256.

    Not in our library10.1590/s0100-879x1998000200008

  140. 140.

    Wewer Albrechtsen N. J. Kuhre R. E. Windelov J. A. Orgaard A. Deacon C. F. Kissow H. (2016 ). Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes. Am. J. Physiol. Endocrinol. Metab. 311 E302–E309.

    Not in our library10.1152/ajpendo.00119.2016

  141. 141.

    Wolfrum C. Stoffel M. (2006 ). Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 3 99–110.

    Not in our library10.1016/j.cmet.2006.01.001

  142. 142.

    Wu M. S. Jeng C. Y. Hollenbeck C. B. Chen Y. D. Jaspan J. Reaven G. M. (1990 ). Does glucagon increase plasma free fatty acid concentration in humans with normal glucose tolerance? J. Clin. Endocrinol. Metab. 70 410–416.

    Not in our library10.1210/jcem-70-2-410

  143. 143.

    Xiao C. Pavlic M. Szeto L. Patterson B. W. Lewis G. F. (2011 ). Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 60 383–390.

    Not in our library10.2337/db10-0763

  144. 144.

    Xu J. Stanislaus S. Chinookoswong N. Lau Y. Y. Hager T. Patel J. (2009 ). Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297 E1105–E1114.

    Not in our library10.1152/ajpendo.00348.2009

  145. 145.

    Yang J. MacDougall M. L. McDowell M. T. Xi L. Wei R. Zavadoski W. J. (2011 ). Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes. BMC Genom. 12:281.

    Not in our library10.1186/1471-2164-12-281

  146. 146.

    Zhang F. Xu X. Zhou B. He Z. Zhai Q. (2011 ). Gene expression profile change and associated physiological and pathological effects in mouse liver induced by fasting and refeeding. PLoS One 6:e27553.

    Not in our library10.1371/journal.pone.0027553

  147. 147.

    Zhou J. Cai X. Huang X. Dai Y. Sun L. Zhang B. (2017 ). A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. Eur. J. Med. Chem. 138 1158–1169.

    Not in our library10.1016/j.ejmech.2017.07.046

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.